ROCKVILLE, Md. – June 2, 2020 – Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development for cell and gene therapies, announced the award of a patent from US Patent and Trademark Office on recombinantly-modified adeno-associated virus (AAV) AAV vectors that are capable of increasing the packaging efficiency of recombinantly-modified adeno-associated virus (rAAV). The invention on rAAV vector is to further modify it by adding Cis-Elements (CisE) near the inverted terminal repeats (ITR) regions, including replication origins, promoters and enhancers. These added CisE are capable of up regulating the replication of an AAV genome AAV viral, thus improving rAAV production efficiency. The use of such additional promoter Cis element sequences increases the production of recombinantly-modified adeno-associated virus 2 to 4 times as much as that from the parental non-modified AAV vector. This is a key component in realizing Vigene’s mission to make gene therapy affordable.
“We are pleased to have this technology available to our clients for AAV GMP production,” stated Dr. Zairen Sun, Vigene’s CEO. “This new technology will significantly improve the yield of AAV vector productions, enabling our clients to attain amounts necessary for therapeutic application more rapidly and at a lower overall cost.”
About Vigene Biosciences
Vigene Biosciences, Inc is a leader in viral vector-based gene delivery for both life science research, gene therapy and cell therapy purposes. Headquartered in Rockville, Maryland, Vigene features 10 fully equipped GMP clean room suites for AAV, lentivirus, retrovirus, adenovirus and plasmids GMP production, respectively. In addition, Vigene also develops and owns a panel of intellectual properties including proprietary high productivity cell lines (suspension and adherent cells) for viral vector packaging and patents for increasing viral vector packaging efficiency. Vigene offers FDA and EMA compliant cGMP production for viral vector and plasmid production with the mission of making gene therapy affordable.
Vigene Contact Information:
Jeffrey Hung, Ph.D.
Chief Commercial Officer